Apigenin
SupplementThe medical score (28) is substantially lower than the community score (55) because the user community holds positive expectations based on Andrew Huberman's recommendation [c2] that are not supported by clinical RCTs on isolated apigenin [s1]. Animal and in vitro evidence [s4, s5] does not automatically translate into human-relevant effects.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Apigenin's popularity is largely driven by Andrew Huberman's sleep stack — but the clinical foundation is weak: no human RCT exists for isolated apigenin, only indirect chamomile extract data. The CD38-inhibition mechanism for NAD⁺ optimization is preclinically interesting but unproven in humans. Community responses are split: some report marginally deeper sleep, others experience morning grogginess and reduced libido. At doses above 100 mg, aromatase-inhibiting activity becomes relevant — particularly for men concerned about testosterone levels.
Description
Natural flavonoid from chamomile and parsley with anxiolytic, sleep-promoting, anti-inflammatory, and potential longevity effects via CD38 inhibition [s1, s2, s4].
Apigenin (4',5,7-trihydroxyflavone) is a plant-derived flavonoid of the flavone subgroup with the molecular formula C₁₅H₁₀O₅. It occurs in particularly high concentrations in chamomile flowers (up to 840 mg per 100 g dry weight), dried parsley leaf (approx. 45 mg/g), as well as in celery and other vegetables [s6, s7]. In nature, apigenin predominantly exists in glycosylated form (O- and C-glycosides), which is hydrolyzed to free apigenin in the intestine. The oral bioavailability of free apigenin is limited; from chamomile extract (apigenin-7-O-glucoside), Cmax is reached after approximately 2 hours [s8]. Liposomal formulations may improve absorption [s9]. Apigenin became widely known in the biohacking and longevity community primarily through Andrew Huberman's sleep protocol (50 mg in the evening). Scientifically, the main evidence derives from animal and cell studies; direct human RCTs on isolated apigenin as a sleep aid or anxiolytic are currently lacking. Chamomile extract studies (with apigenin as the active compound) show modest effects on anxiety and sleep in humans [s1, s2]. In the longevity field, apigenin acts as an inhibitor of the enzyme CD38, which degrades NAD+. Preclinical data demonstrate elevated cellular NAD+ levels as a result [s10, s11]. Clinical confirmation of this effect in humans is not yet available [s10]. Apigenin also inhibits pro-inflammatory cytokines (TNF-α, IL-1β) and exhibits antitumoral properties in cell and animal models, particularly in colorectal carcinoma; these data are exclusively preclinical [s3, s12].
Legal Status (DE)
In Germany, Austria, and Switzerland, apigenin is marketable as an over-the-counter dietary supplement (food supplement) as a naturally occurring flavonoid. Food supplements are not subject to approval requirements but must be notified prior to distribution [s14, s15]. The European Commission initiated a novel food assessment for isolated apigenin in 2026; stricter requirements may apply to standardized isolates [s13].
Mechanism of Action
1. GABA-A receptor modulation: Apigenin competitively binds to the benzodiazepine binding site of the GABA-A receptor [s4, s5]. In animal models it exhibits anxiolytic effects reversible by flumazenil [s4]. In vitro data are contradictory: GABA-induced currents were not consistently potentiated at recombinant α1β2γ2S receptors in Xenopus oocytes [s5]. In vivo, apigenin acts dose-dependently as an anxiolytic at low doses (mice: 3 mg/kg i.p.) and as a sedative at high doses (30–100 mg/kg i.p.) [s4]. 2. CD38 inhibition / NAD+ elevation: Apigenin inhibits the enzyme CD38, an NAD+ hydrolase that is increasingly expressed with age. CD38 inhibition leads to intracellular NAD+ accumulation, which may affect cellular energy metabolism and sirtuin activity [s10, s11]. This effect has so far only been demonstrated in cell and animal studies [s10]. 3. Anti-inflammatory effects: Apigenin suppresses pro-inflammatory cytokines (TNF-α, IL-1β) and modulates NF-κB signaling pathways in vitro [s3]. These effects have been confirmed in animal models but are absent from clinical RCTs [s3]. 4. Antioxidant properties: As a polyphenol, apigenin scavenges free radicals and reduces oxidative stress in cell models [s1, s2]. 5. Neuroprotective / neurotrophic effects: Preclinical data suggest modulation of BDNF and serotonin pathways; clinical evidence is lacking [s2].
Dosing
Schlafverbesserung (Huberman-Protokoll)
- Dose
- 50 mg apigenin
- Frequency
- 1× täglich abends
- Route
- oral
- Duration
- fortlaufend
- Timing
- 30–60 minutes before bedtime
- With food
- optional
Anxiolyse / Stressreduktion
- Dose
- 25–50 mg apigenin
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 4–8 Wochen
- Timing
- morning and/or evening
- With food
- empfohlen
NAD+-Optimierung (CD38-Inhibition, kombiniert mit NMN/NR)
- Dose
- 50–100 mg apigenin
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- with a meal containing some fat (improved absorption)
- With food
- empfohlen
Clinical studies with chamomile extract used up to 1500 mg/day (corresponding to approx. 100 mg apigenin) without serious adverse effects [s1, s2]. A generally accepted tolerable upper intake level for isolated apigenin in humans has not been established. Caution is advised at doses above 300 mg/day due to lack of long-term safety data [s9].
The bioavailability of free apigenin is limited (~30%); fatty meals may moderately improve absorption [s9]. Liposomal formulations show improved pharmacokinetics in preclinical data [s9].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Erschwertes Aufwachen / morgendliche Benommenheit (hangover effect) Multiple Reddit users report difficulty waking and morning grogginess following evening intake [c1, c3]. | gelegentlich | leicht |
| Libidoverlust / vermindertes sexuelles Interesse Apigenin inhibits the enzyme CYP19A1 (aromatase) and can affect estrogenic signaling pathways. User reports of decreased libido and reduced motivation [c1, c4]. | gelegentlich | leicht |
| Stimmungsschwankungen / Reizbarkeit Individual Reddit users report mood lows and irritability with prolonged use [c3]. | selten | leicht |
| Gewichtszunahme (anekdotisch) One user report describes a weight gain of approximately 3 kg with prolonged use; possible connection to hormonal effects (aromatase inhibition), but not clinically established [c3]. | selten | leicht |
| Verstärkte Sedierung / übermäßige Schläfrigkeit bei hohen Dosen In animal models, apigenin acts as a sedative at high doses (≥30 mg/kg i.p.) [s4, s5]. Extrapolation to humans is uncertain; high oral supplement doses can cause pronounced fatigue in some users [c2, c3]. | gelegentlich | leicht |
| CYP-vermittelte Arzneimittelinteraktionen (klinisch relevant) Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 in vitro, potentially increasing plasma levels of substrates (e.g., warfarin, cyclosporine, statins) [s13, s16]. | theoretisch | moderat |
Contraindications
Apigenin may inhibit CYP2C9, thereby slowing warfarin metabolism and increasing bleeding risk [s13, s16].
CYP3A4 inhibition by apigenin may elevate ciclosporin levels and promote nephrotoxicity [s13].
Apigenin exhibits partial estrogenic activity and inhibits aromatase (CYP19A1); its influence on hormone-dependent conditions is unclear; caution is warranted [s1, s16].
No safety data for isolated apigenin in pregnancy; high-dose chamomile extract is not recommended during pregnancy [s1].
Additive GABAergic effects possible; theoretical potentiation of sedation and respiratory depression [s4, s5].
Interactions
Synergistic
Combined CD38 inhibition by apigenin and NAD+ precursor supplementation could synergistically elevate NAD+ levels; preclinical plausibility only so far [s10, s11].
Combination is used in the community for sleep preparation; L-theanine promotes alpha waves and exerts anxiolytic effects. No RCT available for the combination [c4].
Used together in the Huberman sleep protocol; synergistic GABA modulation theoretically plausible, no combined RCT [c2].
Apigenin and melatonin are frequently combined to improve sleep onset and sleep quality. Apigenin exerts sedative effects via GABA receptors, while melatonin regulates circadian rhythm. The combination is considered additive and well tolerated.
Apigenin and quercetin both inhibit the enzyme CD38, leading to elevated intracellular NAD+ levels. Preclinical studies have described senolytic/senomorphic activity for both flavonoids, which may complement each other in combination.
Apigenin reduces SASP secretion from senescent cells, while fisetin selectively eliminates senescent cells. The combination is recommended by some longevity protocols to address both senescence clearance and SASP suppression.
Both substances can lower cortisol levels and improve sleep quality. Apigenin acts via GABAergic mechanisms, ashwagandha via withanolide-mediated stress axis modulation. Combined evening administration appears plausibly synergistic.
Caution
CYP2C9 inhibition may increase anticoagulant levels. INR monitoring recommended with concomitant use [s13, s16].
CYP3A4 inhibition may increase statin levels and raise the risk of myopathy [s13].
CYP modulation and weak estrogenic/antiestrogenic properties of apigenin may theoretically affect the efficacy of hormonal contraceptives [s16].
Additive GABAergic effect possible; enhanced sedation and potential respiratory depression [s4, s5].
CYP interactions and additive toxicity possible during oncological treatment; consultation with oncologist required [s13].
Apigenin inhibits CYP2C9, CYP2C19, and CYP3A4 as well as P-glycoprotein in vitro. Berberine is also a CYP inhibitor. A combination could impair the metabolism of both substances and shared drug substrates.
Apigenin has weak estrogenic and antiestrogenic properties; DIM actively modulates estrogen metabolism. A combination may unpredictably affect hormonal balance, particularly in hormone-sensitive conditions.
Calcium-D-glucarate inhibits beta-glucuronidase and promotes estrogen excretion. Since apigenin itself exhibits estrogenic/antiestrogenic activity, both substances may interact in their effect on estrogen levels and lead to excessive reduction.
Studies
Tier A — High Evidence
Outcome: Reduction of GAD-7 anxiety symptoms and sleep parameters
Effect Size: Chamomile extract significantly superior to placebo in anxiety reduction (p<0.05); moderate effect size
Tier B — Moderate Evidence
Outcome: Summary of therapeutic potentials of apigenin
Effect Size: Comprises preclinical and few clinical studies; no meta-analysis effect size reported
Outcome: Antitumoral effect of apigenin in animal models
Effect Size: Significant tumor size reduction in animal models; no human transferability demonstrated
Tier C — Low Evidence
Outcome: GABA-A receptor binding and anxiolytic effect
Effect Size: Anxiolytic at 3 mg/kg i.p. (mice); sedative at 30–100 mg/kg i.p.
Outcome: CD38 inhibition and NAD+ increase
Effect Size: Significant CD38 inhibition and NAD+ accumulation in cell models
Outcome: GABAergic transmission and sedative effect
Effect Size: No consistent GABA-A current modulation in vitro; in vivo sedative effect via GABAergic pathways
Community Evidence
Top reported benefits
- Mild relaxation before sleep
- Somewhat deeper sleep (in a subset of users)
- Mild anxiolytic effect
- Potential longevity effect (CD38 inhibition) within NAD+ protocols
Top reported issues
- No noticeable effect on sleep (most common complaint)
- Difficulty waking / morning grogginess
- Loss of libido and reduced motivation with prolonged use
- Mood swings / irritability
Several users note that apigenin at high doses (>100 mg) may act as an aromatase inhibitor, potentially leading to reduced testosterone in men and altered estrogen/progesterone ratios in women [c1, c4]. Its popularity is largely driven by Andrew Huberman's recommendation without direct human RCT evidence for isolated apigenin [c2].
Scientific Sources
- The Therapeutic Potential of Apigenin
Salehi B, Venditti A, Sharifi-Rad M, et al. (2019). International Journal of Molecular SciencesBPMID:30939534DOI - CD38 inhibition by quercetin and apigenin increases NAD+ levels in cells (Longecity forum discussion citing primary literature)
Various community authors citing Escande C, et al. (2019). Longecity / Primary: Cell MetabolismCLink - NMN and Apigenin: Science of CD38 Inhibition for Longevity
NMN Labo Editorial Team (2023). NMN Labo BlogCLink - Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models
Singh D, Gupta M, Sarwat M, et al. (2022). Critical Reviews in Oncology/HematologyAPMID:35752426DOI - Pharmacokinetic properties and drug interactions of apigenin
Si H, Liu D (2016). PubMed / Journal unbekanntBPMID:27766890 - Nahrungsergänzungsmittel: Rechtliche Grundlagen – BVL
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) (2025). BVL PressemitteilungALink - Nahrungsergänzungsmittel – Lebensmittelsicherheit (BLV Schweiz)
Bundesamt für Lebensmittelsicherheit und Veterinärwesen (BLV) (2024). BLV SchweizALink - Apigenin: What Is It, Uses, Benefits, Dosage
Salehi B, et al. (cited via Ro.co summary) (2019). Ro Health Guide / Primary: Int J Mol SciCLink - Apigenin: a natural molecule at the intersection of sleep and longevity
Hemdan S, Sherif A, El-Sayed A, et al. (2024). PMC / FrontiersBLink - Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta-analysis
Taheri M, Hassanpour M, Ghafouri-Fard S, et al. (2024). Cancer Medicine / PMCAPMID:39254067 - Flavonoids as GABAA receptor ligands: the whole story?
Karim N, Khan I, Halim S, et al. (2016). Journal of Pharmacological Sciences / PMCBLink - Involvement of GABAergic pathway in the sedative activity of apigenin, the main flavonoid from Passiflora quadrangularis pericarp
Coleta M, Batista MT, Campos MG, et al. (2006). Journal of EthnopharmacologyCLink - Apigenin - Wikipedia
Wikipedia Contributors (2024). WikipediaDLink - A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota
Wang M, Firrman J, Liu L, et al. (2019). BioMed Research InternationalBDOI - Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults
Reinboth M, Wolffram S, Abraham G, et al. (2022). Free Radical Biology and MedicineBDOI - Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
Patel M, Tran H, Nguyen A, et al. (2021). Frontiers in PharmacologyBDOI
Community Sources
Storage
Unopened
Store dry, cool (15–25 °C), protected from light in original packaging.
Opened
Keep container tightly closed; avoid moisture and direct sunlight.
Notes
Apigenin is light-sensitive; UV exposure can degrade the flavonoid. In powder form, watch for clumping.